Acadia Pharmaceuticals | ACAD - Debt


Acadia Pharmaceuticals reported $50.79M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 9.64M 3.53M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
Eisai JPY 186.08B 50.58B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
J&J USD 54.99B 7.05B Mar/2026
Moderna USD 1.3B 7M Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Prothena USD 7.65M 1.43M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026